$4.01 Million in Sales Expected for Five Prime Therapeutics Inc (NASDAQ:FPRX) This Quarter
Brokerages expect that Five Prime Therapeutics Inc (NASDAQ:FPRX) will post $4.01 million in sales for the current fiscal quarter, according to Zacks Investment Research. Five analysts have provided estimates for Five Prime Therapeutics’ earnings. The highest sales estimate is $8.34 million and the lowest is $2.00 million. Five Prime Therapeutics posted sales of $4.03 million in the same quarter last year, which suggests a negative year over year growth rate of 0.5%. The business is scheduled to issue its next quarterly earnings results on Tuesday, February 25th.
According to Zacks, analysts expect that Five Prime Therapeutics will report full year sales of $15.04 million for the current year, with estimates ranging from $11.70 million to $20.00 million. For the next financial year, analysts forecast that the firm will report sales of $33.08 million, with estimates ranging from $20.00 million to $62.30 million. Zacks’ sales averages are a mean average based on a survey of research firms that that provide coverage for Five Prime Therapeutics.
Five Prime Therapeutics (NASDAQ:FPRX) last announced its quarterly earnings results on Wednesday, November 6th. The biotechnology company reported ($1.03) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.95) by ($0.08). Five Prime Therapeutics had a negative net margin of 921.30% and a negative return on equity of 65.39%. The firm had revenue of $2.98 million during the quarter, compared to analyst estimates of $4.33 million.
Shares of FPRX stock traded up $0.28 on Friday, hitting $4.37. The stock had a trading volume of 382,931 shares, compared to its average volume of 381,204. Five Prime Therapeutics has a twelve month low of $3.18 and a twelve month high of $13.84. The firm has a market cap of $148.84 million, a P/E ratio of -1.06 and a beta of 2.39. The company has a current ratio of 6.93, a quick ratio of 6.93 and a debt-to-equity ratio of 0.26. The company has a fifty day moving average price of $3.83 and a two-hundred day moving average price of $5.20.
In related news, major shareholder Bvf Partners L. P/Il bought 525,070 shares of Five Prime Therapeutics stock in a transaction that occurred on Monday, October 7th. The stock was purchased at an average cost of $3.75 per share, with a total value of $1,969,012.50. The acquisition was disclosed in a filing with the SEC, which is available at the SEC website. Also, major shareholder Bvf Partners L. P/Il bought 1,120,010 shares of Five Prime Therapeutics stock in a transaction that occurred on Friday, November 22nd. The stock was bought at an average cost of $3.40 per share, with a total value of $3,808,034.00. The disclosure for this purchase can be found here. Over the last ninety days, insiders purchased 3,498,133 shares of company stock valued at $14,201,410. Company insiders own 7.10% of the company’s stock.
Hedge funds and other institutional investors have recently made changes to their positions in the stock. Rhumbline Advisers boosted its stake in Five Prime Therapeutics by 8.9% in the 3rd quarter. Rhumbline Advisers now owns 57,190 shares of the biotechnology company’s stock worth $222,000 after purchasing an additional 4,657 shares during the period. Man Group plc lifted its position in Five Prime Therapeutics by 15.2% during the 3rd quarter. Man Group plc now owns 1,336,847 shares of the biotechnology company’s stock worth $5,180,000 after buying an additional 176,436 shares in the last quarter. Renaissance Technologies LLC lifted its position in Five Prime Therapeutics by 86.5% during the 2nd quarter. Renaissance Technologies LLC now owns 1,149,200 shares of the biotechnology company’s stock worth $6,930,000 after buying an additional 533,100 shares in the last quarter. Morgan Stanley lifted its position in Five Prime Therapeutics by 1,167.3% during the 2nd quarter. Morgan Stanley now owns 258,317 shares of the biotechnology company’s stock worth $1,558,000 after buying an additional 237,933 shares in the last quarter. Finally, JPMorgan Chase & Co. lifted its position in Five Prime Therapeutics by 32.2% during the 2nd quarter. JPMorgan Chase & Co. now owns 321,907 shares of the biotechnology company’s stock worth $1,947,000 after buying an additional 78,404 shares in the last quarter. 73.29% of the stock is owned by hedge funds and other institutional investors.
Five Prime Therapeutics Company Profile
Five Prime Therapeutics, Inc, a clinical-stage biotechnology company, focuses on the discovery and development of innovative protein therapeutics. The company's product candidates comprise Bemarituzumab, an antibody that inhibits fibroblast growth factor receptor 2b, or FGFR2b, which is in Phase III clinical trials to treat patients with gastric or gastroesophageal junction and GEJ cancer; and FPA150, a CD8 T cell checkpoint inhibitor antibody that targets B7-H4 in various cancers, as well as FPT155, a soluble CD80 fusion protein that enhances co-stimulation of T cells through CD28.
Further Reading: What are high-yield dividend stocks?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Five Prime Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Five Prime Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.